Welcome to our dedicated page for Kura Oncology news (Ticker: KURA), a resource for investors and traders seeking the latest updates and insights on Kura Oncology stock.
Kura Oncology, Inc. reports news on its precision oncology business, including commercialization of KOMZIFTI™ (ziftomenib), an FDA-approved once-daily oral menin inhibitor for adults with relapsed or refractory NPM1-mutated acute myeloid leukemia. Company updates also cover small-molecule drug candidates designed to target cancer signaling pathways across hematologic malignancies and solid tumors.
Recurring KURA developments include financial results, corporate updates, clinical data presentations, collaboration-related milestones, healthcare conference participation and Nasdaq inducement grants. News on darlifarnib (KO-2806) follows the company’s farnesyl transferase inhibitor program, including studies in combination with cabozantinib for clear cell renal cell carcinoma.
Kura Oncology (Nasdaq: KURA) and Kyowa Kirin reported long-term Phase 1/2 KOMET-007 data for ziftomenib + 7+3 in newly diagnosed NPM1-m and KMT2A-r AML.
12‑month OS was 94% for NPM1-m and 71% for KMT2A-r; CRc reached 96% and 90%, with high MRD negativity and a generally manageable safety profile supporting the ongoing Phase 3 KOMET-017 program.
Kura Oncology (Nasdaq: KURA) granted inducement stock options on June 1, 2026 to four new employees under its 2023 Inducement Option Plan. The awards cover 53,000 shares at an exercise price of $9.04 per share, vesting over four years under Nasdaq Listing Rule 5635(c)(4).
Kura Oncology (Nasdaq: KURA) reported preliminary Phase 1a data for darlifarnib + adagrasib, showing confirmed objective response rates of 67% in KRAS G12C pancreatic cancer, 50% in lung cancer and 29% in KRAS inhibitor-naïve colorectal cancer.
The company plans a new darlifarnib combination platform study, starting with darlifarnib + daraxonrasib in 2L+ KRAS-mutant pancreatic cancer, expected to enter Phase 1a in early 2027, and will host a virtual investor event on June 3, 2026.
Kura Oncology (Nasdaq: KURA) and Kyowa Kirin reported updated Phase 1a/b KOMET-007 data in relapsed/refractory NPM1-mutated AML using ziftomenib + venetoclax/azacitidine.
At 600 mg, venetoclax-naïve patients showed 87% ORR, 70% CRc and median OS not reached; venetoclax-experienced patients had 48% ORR, 24% CRc. The triplet showed a generally manageable safety profile with low differentiation syndrome and limited QTc events.
Kura Oncology (Nasdaq: KURA) reported Phase 1a data from the FIT-001 trial of darlifarnib + adagrasib in KRAS G12C-mutated advanced solid tumors.
- Tumor shrinkage in 77% (20/26) of response-evaluable patients; 94% (15/16) in KRASi-naïve patients
- ORR: 67% in PDAC, 50% in NSCLC, 29% in KRASi-naïve CRC
- Clinical activity seen across dose levels and tumor types, including heavily pretreated and KRASi-experienced patients
- 37% of patients remained on treatment at March 25, 2026 cutoff
- Combination described as well tolerated with a manageable safety profile; darlifarnib 8 mg will not be advanced further
- ASCO 2026 presentation on May 30, and a virtual investor event on June 3, 2026
Kura Oncology (Nasdaq: KURA) will participate in the TD Cowen 7th Annual Oncology Innovation Summit on May 26, 2026. Management will join a virtual fireside chat at 1:30 p.m. ET / 10:30 a.m. PT, with live and archived webcasts available via the company’s investor website.
Kura Oncology (Nasdaq: KURA) reported first quarter 2026 results and launch metrics for AML drug KOMZIFTI (ziftomenib). Net product revenue reached $5.8 million with 85 new patient starts, 157 total prescriptions and >93% payer coverage across >12 million lives.
Total collaboration revenue was $12.5 million. Kura reported a net loss of $73.3 million, driven by higher R&D and SG&A expenses. Cash, cash equivalents and short-term investments totaled $580.8 million, and together with $180 million anticipated collaboration payments, are expected to fund the ziftomenib AML program through first KOMET-017 Phase 3 topline results, anticipated in 2028.
Kura Oncology (Nasdaq: KURA) and Kyowa Kirin will present updated frontline data from the Phase 1 KOMET-007 trial of ziftomenib + 7+3 in 99 newly diagnosed NPM1-m or KMT2A-r AML patients at the EHA 2026 Congress.
Reported results include CRc rates of 96% (NPM1-m) and 90% (KMT2A-r), MRD-negativity above 80%, and durable responses. A Phase 3 KOMET-017 trial is enrolling, and a virtual investor call is scheduled for June 3, 2026.
Kura Oncology (Nasdaq: KURA) will participate in the Bank of America Securities 2026 Healthcare Conference on May 13, 2026. Management is scheduled for a fireside chat at 6:00 p.m. ET / 3:00 p.m. PT. A live webcast and archived replay will be available on the company Investors website.
Kura Oncology (Nasdaq: KURA) will report first quarter 2026 financial results after market close on Tuesday, May 12, 2026. Management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT to discuss results and provide a corporate update. A live webcast and archived replay will be available on the company Investors website.